BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22482451)

  • 1. Huntington disease and the huntingtin protein.
    Zheng Z; Diamond MI
    Prog Mol Biol Transl Sci; 2012; 107():189-214. PubMed ID: 22482451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making (anti-) sense out of huntingtin levels in Huntington disease.
    Evers MM; Schut MH; Pepers BA; Atalar M; van Belzen MJ; Faull RL; Roos RA; van Roon-Mom WM
    Mol Neurodegener; 2015 Apr; 10():21. PubMed ID: 25928884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease.
    Keryer G; Pineda JR; Liot G; Kim J; Dietrich P; Benstaali C; Smith K; Cordelières FP; Spassky N; Ferrante RJ; Dragatsis I; Saudou F
    J Clin Invest; 2011 Nov; 121(11):4372-82. PubMed ID: 21985783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huntington's disease: from pathology and genetics to potential therapies.
    Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
    Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.
    Graham RK; Slow EJ; Deng Y; Bissada N; Lu G; Pearson J; Shehadeh J; Leavitt BR; Raymond LA; Hayden MR
    Neurobiol Dis; 2006 Feb; 21(2):444-55. PubMed ID: 16230019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
    Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
    Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.
    Weiss KR; Kimura Y; Lee WC; Littleton JT
    Genetics; 2012 Feb; 190(2):581-600. PubMed ID: 22095086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.
    Bard J; Wall MD; Lazari O; Arjomand J; Munoz-Sanjuan I
    J Biomol Screen; 2014 Feb; 19(2):191-204. PubMed ID: 24196395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
    Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
    FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntington's disease does not appear to increase the risk of diabetes mellitus.
    Boesgaard TW; Nielsen TT; Josefsen K; Hansen T; Jørgensen T; Pedersen O; Nørremølle A; Nielsen JE; Hasholt L
    J Neuroendocrinol; 2009 Sep; 21(9):770-6. PubMed ID: 19602103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntingtin processing in pathogenesis of Huntington disease.
    Qin ZH; Gu ZL
    Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.
    Oliveira JM
    J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of cholesterol metabolism in Huntington's disease.
    Leoni V; Caccia C
    Biochem Biophys Res Commun; 2014 Apr; 446(3):697-701. PubMed ID: 24525128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin can paradoxically protect neurons from death.
    Zuchner T; Brundin P
    Cell Death Differ; 2008 Mar; 15(3):435-42. PubMed ID: 17975550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.